Researchers shared long-term follow-up data from the Colchicine-PCI trial, which compared colchicine administration before PCI with a placebo.

Out of more than 250 abstracts submitted at its annual meeting in Boston, SCCT named one winner and two runners-up. 

COVID-19 opened the eyes of many cardiology researchers that infections may promote inflammation in atherosclerotic plaques, leading to cardiac events.

Creating these complex structures with 3D printing alone has never been possible—until now. 

Researchers tracked data from nearly 7,000 TAVR patients for two years, focusing on all-cause mortality and heart failure hospitalizations.

Targeting immune cells that play a key role in the development of atrial fibrillation could give cardiologists a new way to treat the disease.

The FDA Circulatory System Devices Panel is set to review the PMA submissions for the ReCor and Medtronic renal denervation systems to treat patients with uncontrolled hypertension.

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.